Tharimmune licenses clinical-stage TH104 for chronic pruritis; PBC Phase 2 trial planned

Canton Strategic Holdings, Inc.

Exclusive worldwide license from Avior for TH104 (AV104) and TH103; targets chronic pruritis in PBC, an orphan liver disease.
Upfront mid-six-digit fee plus installments; up to $24.25M in development milestones plus sales-based payments and royalties.
Plans to initiate Phase 2 trial in PBC patients within ~12 months after FDA alignment; expects top-line data thereafter.
TH104 uses buccal film delivery with dual mechanism on μ-opioid and κ-opioid receptors and IL-17 inhibition.
CEO Randy Milby says license agreement represents shift to clinical development focus.

Key facts

Extracted from this filing and checked against the source text.

Material Agreements SEC 8-K Item 1.01/1.02 confidence 0.9

Canton Strategic Holdings, Inc. entered into Avior Patent License Agreement with Avior Inc. d/b/a Avior Bio, LLC valued at $24,250,000 (effective 2023-11-03).

Action: entry
Agreement: license
Counterparty: Avior Inc. d/b/a Avior Bio, LLC
Value: $24,250,000
Effective: 2023-11-03

Exact text from the filing

Tharimmune, Inc. (the “Company”) entered into a patent license agreement (the “Avior Patent License Agreement”) with Avior Inc. d/b/a Avior Bio, LLC (“Avior”)

View on SEC.gov

281 material agreements filed in the last 30 days. Browse all material agreements →

Canton Strategic Holdings, Inc. filing history →

Source: SEC EDGAR

accession 0001493152-23-039743

view filing index on sec.gov

view primary document

Machine-readable: JSON · Markdown · Plain text

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.